Evaluation of the efficacy of bronchial arterial infusion chemotherapy for the treatment of central non-small cell lung cancer.
- Author:
Dong YAN
1
;
Chun-wu ZHOU
;
De-zhong LIU
;
Yan CHEN
;
Hui-ying ZENG
;
Huai LI
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; pathology; surgery; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; therapeutic use; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; drug therapy; pathology; surgery; Carcinoma, Squamous Cell; drug therapy; pathology; surgery; Cisplatin; administration & dosage; Epirubicin; administration & dosage; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Lung Neoplasms; drug therapy; pathology; surgery; Male; Middle Aged; Mitomycin; administration & dosage; Neoplasm Staging; Survival Rate
- From: Chinese Journal of Oncology 2011;33(4):302-304
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the long-term efficacy of bronchial arterial infusion (BAI) chemotherapy in the treatment of centeral non-small cell lung cancer.
METHODSFifty-eight patients with central non-small-cell lung cancer, who were assessed as difficult operable or non-operable by imaging examination, received BAI of cisplatin, epirubicin and mitomycin alone or in combination. It includes 51 cases of squamous cell carcinoma, 6 cases of adenocarcinoma and 1 case of adenosquamous carcinoma. The cinical stage before BAI wasIIb in 3 cases, IIIa in 26 cases and IIIb in 29 cases. Long term follow-up was conducted and the results were statistically analyzed.
RESULTSThe total effective rate of BAI was 43.1%. The mediam survival (MS) of all 58 patients was 29.1 months. 31 patients after BAI became operable and were resected, had a median survival of 65.2 months. 27 patients after BAI were not resected and had a MS of 15.9 months. There was a significant difference between the patients who had been resected and not. The MS of IIIa stage patients was 39.0 months, and IIIb stage 20.4 months.
CONCLUSIONBronchial arterial infusion chemotherapy is a better choice with a definite efficacy for treatment of center-based NSCLC patients, estimated as difficult operable but without distant metastasis.
